Literature DB >> 10228850

Clinical and biological features of t1 ductal adenocarcinoma of the pancreas.

S Takao1, H Shinchi, K Sha, S Natsugoe, S Maenohara, T Suenaga, Y Nishimata, T Aikou.   

Abstract

BACKGROUND/AIMS: The impact of tumor size on tumor development and long-term prognosis is still controversial for patients with ductal adenocarcinoma of the pancreas. We investigated the clinicopathological and biological features of ductal adenocarcinoma limited to the pancreas without direct histological extrapancreatic invasion (t1 tumor).
METHODOLOGY: The clinical records of 86 patients who underwent surgery for ductal adenocarcinoma of the pancreas were reviewed to determine clinical features, histopathological findings, operative management and outcomes. Immunohistochemical staining of the p53 tumor suppressor gene (p53) was performed for the resected specimens.
RESULTS: Only 10 (12%) of the 86 resected ductal adenocarcinomas of the pancreas were t1 tumors. Six of the 10 patients with t1 tumors survived for more than 5 years. The rates of nodal metastasis (10%) and neural plexus invasion (0%) in t1 tumors were significantly lower than those in non-t1 tumors, although the rates of blood-borne metastasis (30%) and p53 expression (50%) in t1 tumors were the same as those in non-t1 tumors.
CONCLUSIONS: Curative resection contributes to a satisfactory long-term prognosis of patients with t1 tumor of the pancreas as a result of the low rates of both nodal metastasis and neural plexus invasion associated with this procedure. In patients with t1 tumor of the pancreas, a satisfactory long-term prognosis can be assured as a result of the low rates of both nodal metastasis and neural plexus invasion associated with curative resection.

Entities:  

Mesh:

Year:  1999        PMID: 10228850

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  2 in total

1.  Risk factors influencing recurrence following resection of pancreatic head cancer.

Authors:  De-Qing Mu; Shu-You Peng; Guo-Feng Wang
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

2.  Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer.

Authors:  H Shinchi; K Maemura; H Noma; Y Mataki; T Aikou; S Takao
Journal:  Br J Cancer       Date:  2007-04-17       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.